Tumor Immune Microenvironment Landscape in Glioma Identifies a Prognostic and Immunotherapeutic Signature

被引:6
作者
Zhang, Chunyu [1 ]
Guo, Lirui [1 ]
Su, Zhongzhou [2 ]
Luo, Na [3 ,4 ]
Tan, Yinqiu [5 ]
Xu, Pengfei [6 ]
Ye, Liguo [1 ]
Tong, Shiao [1 ]
Liu, Haitao [7 ]
Li, Xiaobin [2 ]
Chen, Qianxue [1 ]
Tian, Daofeng [1 ]
机构
[1] Wuhan Univ, Renmin Hosp, Dept Neurosurg, Wuhan, Peoples R China
[2] Huzhou Univ, Affiliated Cent Hosp, Huzhou Cent Hosp, Dept Neurosurg, Huzhou, Peoples R China
[3] Peking Univ, China Japan Friendship Sch Clin Med, Beijing, Peoples R China
[4] China Japan Friendship Hosp, Dept Neurosurg, Beijing, Peoples R China
[5] Huazhong Univ Sci & Technol, Union Hosp, Dept Neurosurg, Tongji Med Coll, Wuhan, Peoples R China
[6] Sun Yat Sen Univ, Affiliated Hosp 7, Shenzhen, Peoples R China
[7] Jiaxing Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, Jiaxing, Peoples R China
关键词
glioma; TIME landscape; prognosis; CIBERSORT; immune; CANCER-IMMUNOTHERAPY; CELL ACCUMULATION; RNA-SEQ; MACROPHAGES; GLIOBLASTOMA; PROGRESSION; NIVOLUMAB; BLOCKADE; GROWTH; PEMBROLIZUMAB;
D O I
10.3389/fcell.2021.717601
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The tumor immune microenvironment (TIME) has been recognized to be associated with sensitivity to immunotherapy and patient prognosis. Recent research demonstrates that assessing the TIME patterns on large-scale samples will expand insights into TIME and will provide guidance to formulate immunotherapy strategies for tumors. However, until now, thorough research has not yet been reported on the immune infiltration landscape of glioma. Herein, the CIBERSORT algorithm was used to unveil the TIME landscape of 1,975 glioma observations. Three TIME subtypes were established, and the TIMEscore was calculated by least absolute shrinkage and selection operator (LASSO)-Cox analysis. The high TIMEscore was distinguished by an elevated tumor mutation burden (TMB) and activation of immune-related biological process, such as IL6-JAK-STAT3 signaling and interferon gamma (IFN-gamma) response, which may demonstrate that the patients with high TIMEscore were more sensitive to immunotherapy. Multivariate analysis revealed that the TIMEscore could strongly and independently predict the prognosis of gliomas [Chinese Glioma Genome Atlas (CGGA) cohort: hazard ratio (HR): 2.134, p < 0.001; Gravendeel cohort: HR: 1.872, p < 0.001; Kamoun cohort: HR: 1.705, p < 0.001; The Cancer Genome Atlas (TCGA) cohort: HR: 2.033, p < 0.001; the combined cohort: HR: 1.626, p < 0.001], and survival advantage was evident among those who received chemotherapy. Finally, we validated the performance of the signature in human tissues from Wuhan University (WHU) dataset (HR: 15.090, p = 0.008). Our research suggested that the TIMEscore could be applied as an effective predictor for adjuvant therapy and prognosis assessment.
引用
收藏
页数:16
相关论文
共 84 条
[11]   Elements of cancer immunity and the cancer-immune set point [J].
Chen, Daniel S. ;
Mellman, Ira .
NATURE, 2017, 541 (7637) :321-330
[12]   TGFβ2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells [J].
Corbet, Cyril ;
Bastien, Estelle ;
de Jesus, Joao Pedro Santiago ;
Dierge, Emeline ;
Martherus, Ruben ;
Vander Linden, Catherine ;
Doix, Bastien ;
Degavre, Charline ;
Guilbaud, Celine ;
Petit, Laurenne ;
Michiels, Carine ;
Dessy, Chantal ;
Larondelle, Yvan ;
Feron, Olivier .
NATURE COMMUNICATIONS, 2020, 11 (01)
[13]   Microenvironmental regulation of tumour angiogenesis [J].
de Palma, Michele ;
Biziato, Daniela ;
Petrova, Tatiana V. .
NATURE REVIEWS CANCER, 2017, 17 (08) :457-474
[14]   CHI3L1, NTRK2, 1p/19q and IDH Status Predicts Prognosis in Glioma [J].
Deluche, Elise ;
Bessette, Barbara ;
Durand, Stephanie ;
Caire, Francois ;
Rigau, Valerie ;
Robert, Sandrine ;
Chaunavel, Alain ;
Forestier, Lionel ;
Labrousse, Francois ;
Jauberteau, Marie-Odile ;
Durand, Karine ;
Lalloue, Fabrice .
CANCERS, 2019, 11 (04)
[15]  
DU L, 2017, CHINESE NEUROSURGICA, V3, P23, DOI DOI 10.1186/S41016-017-0086-3
[16]   The promise of immunotherapy in head and neck squamous cell carcinoma [J].
Economopoulou, P. ;
Agelaki, S. ;
Perisanidis, C. ;
Giotakis, E. I. ;
Psyrri, A. .
ANNALS OF ONCOLOGY, 2016, 27 (09) :1675-1685
[17]  
Fan T, 2021, AGING-US, V13, P2397, DOI 10.18632/aging.202269
[18]   Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck [J].
Ferris, R. L. ;
Blumenschein, G., Jr. ;
Fayette, J. ;
Guigay, J. ;
Colevas, A. D. ;
Licitra, L. ;
Harrington, K. ;
Kasper, S. ;
Vokes, E. E. ;
Even, C. ;
Worden, F. ;
Saba, N. F. ;
Iglesias Docampo, L. C. ;
Haddad, R. ;
Rordorf, T. ;
Kiyota, N. ;
Tahara, M. ;
Monga, M. ;
Lynch, M. ;
Geese, W. J. ;
Kopit, J. ;
Shaw, J. W. ;
Gillison, M. L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1856-1867
[19]   Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data [J].
Finotello, Francesca ;
Mayer, Clemens ;
Plattner, Christina ;
Laschober, Gerhard ;
Rieder, Dietmar ;
Hackl, Hubert ;
Krogsdam, Anne ;
Loncova, Zuzana ;
Posch, Wilfried ;
Wilflingseder, Doris ;
Sopper, Sieghart ;
Ijsselsteijn, Marieke ;
Brouwer, Thomas P. ;
Johnson, Douglas ;
Xu, Yaomin ;
Wang, Yu ;
Sanders, Melinda E. ;
Estrada, Monica V. ;
Ericsson-Gonzalez, Paula ;
Charoentong, Pornpimol ;
Balko, Justin ;
de Miranda, Noel Filipe da Cunha Carvahlo ;
Trajanoski, Zlatko .
GENOME MEDICINE, 2019, 11 (1)
[20]   Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer [J].
Fu, Hangcheng ;
Zhu, Yu ;
Wang, Yiwei ;
Liu, Zheng ;
Zhang, Junyu ;
Xie, Huyang ;
Fu, Qiang ;
Dai, Bo ;
Ye, Dingwei ;
Xu, Jiejie .
CLINICAL CANCER RESEARCH, 2018, 24 (13) :3069-3078